{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=6", "query": { "condition": "Colon/Rectal Cancer Rectal Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2447, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:04:47.122Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003843", "title": "Irinotecan in Treating Patients With Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "1998-10", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2015-02-16", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003843" }, { "nct_id": "NCT00739453", "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2008-10-23", "completion_date": "2012-03-03", "has_results": false, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00739453" }, { "nct_id": "NCT00601172", "title": "A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nausea and Vomiting, Chemotherapy-Induced" ], "interventions": [ { "name": "Casopitant", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2008-03-10", "completion_date": "2009-04-13", "has_results": true, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 23, "location_summary": "Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601172" }, { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT00548236", "title": "The Active After Cancer Trial (AACT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "Telephone-Based exercise intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2007-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 9, "location_summary": "La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Concord", "state": "New Hampshire" }, { "city": "Hooksett", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548236" }, { "nct_id": "NCT02972034", "title": "Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Colorectal Cancer" ], "interventions": [ { "name": "MK-8353", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-01-13", "completion_date": "2022-12-02", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • Nashville, Tennessee", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972034" }, { "nct_id": "NCT07479381", "title": "Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer (Diagnosis)" ], "interventions": [], "intervention_types": [], "sponsor": "Harbinger Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 14, "start_date": "2026-03-20", "completion_date": "2026-03-27", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07479381" }, { "nct_id": "NCT05733000", "title": "CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Lung Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Urothelial Carcinoma", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Biliary Tract Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Lung Adenocarcinoma", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Biliary Tract Carcinoma", "Refractory Colorectal Carcinoma", "Refractory Gastroesophageal Junction Adenocarcinoma", "Refractory Lung Adenocarcinoma", "Refractory Ovarian Carcinoma", "Refractory Pancreatic Carcinoma", "Refractory Urothelial Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Devimistat", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-03-08", "completion_date": "2030-03-04", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733000" }, { "nct_id": "NCT02282722", "title": "Improving Informed Consent for Palliative Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Colorectal Cancer", "Metastatic Pancreatic Cancer", "Unresectable Pancreatic Cancer" ], "interventions": [ { "name": "Investigational informed consent for chemotherapy", "type": "OTHER" }, { "name": "Usual, standard-of-care informed consent for chemotherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 216, "start_date": "2015-06-10", "completion_date": "2017-09-27", "has_results": true, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 8, "location_summary": "San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" }, { "city": "South Weymouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282722" }, { "nct_id": "NCT00060411", "title": "A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-15T12:04:47.122Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060411" } ] }